查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829858

2025年癌症診斷全球市場報告

Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，癌症診斷市場規模強勁成長，從2024年的232.4億美元成長到2025年的255億美元，複合年成長率為9.7%。預測期內的成長歸因於癌症發生率的上升、癌症篩檢計畫、個人化醫療以及公眾意識的提升。

預計未來幾年癌症診斷市場將快速成長，到2029年將達到400.7億美元，年複合成長率（CAGR）為12.0%。預測期內的成長可歸因於新興市場的成長、監管支援、人工智慧 (AI) 和機器學習以及早期檢測和介入。預測期內的主要趨勢包括液態切片、多組體學方法、就地檢驗、篩檢和早期療育宣傳活動。

癌症診斷涵蓋用於檢測個別癌症存在的流程、檢測和技術。該領域涵蓋多種旨在識別、分期和表徵癌症的方法，以便及時有效地進行治療。

我們在癌症診斷領域的主要產品包括伴隨診斷和分子診斷。分子診斷涉及檢測指示癌症存在的特定蛋白質、基因和分子的檢測程序。癌症診斷方法包括切片檢查、內視鏡檢查、腫瘤生物標記檢測和影像學檢查。這些診斷工具適用於多種癌症類型，包括子宮頸癌、乳癌、肝癌、血癌、腎臟癌、大腸癌、胰臟癌、卵巢癌和黑色素瘤。它們的最終用戶包括癌症研究機構、診斷實驗室、醫院和相關組織。

2025年春季，美國關稅突然上調及其引發的貿易摩擦對醫療設備產業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰進一步加劇了形勢，因為由於關稅而更換供應商通常需要醫療設備重新認證，導致市場准入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供癌症診斷市場統計數據，例如全球市場規模、區域佔有率、癌症診斷市場佔有率的競爭對手、詳細的癌症診斷細分市場、市場趨勢和商業機會，以及您在癌症診斷行業取得成功所需的數據。本癌症診斷市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的一切觀點。

未來五年的預測成長率為12.0%，較我們先前對該市場的預測略有下降0.6%。這一下降主要源於美國與其他國家之間關稅的影響，這可能會直接影響到美國，導致螢光原位雜合反應(FISH) 探針和數位病理切片掃描儀的供應鏈中斷，而這些設備主要來自以色列和荷蘭等主要地區。

癌症診斷市場的一個關鍵促進因素是各類癌症的高發生率，迫使更多人接受診斷和治療。世界衛生組織 (WHO) 的數據顯示，癌症發生率的上升已使其成為全球第二大死因。美國國家癌症研究所 (NCI) 預測，到 2030 年，每年新增癌症病例將增加至 2,360 萬人。

預計癌症診斷設備市場的成長將主要受到肺癌發病率上升的推動。肺癌是一種廣泛傳播且致命的癌症，其特徵是肺組織中異常細胞不受控制地生長。癌症診斷設備在肺癌的檢測、診斷和監測中發揮關鍵作用，幫助醫護人員識別癌症的存在、確定其類型和分期，並指導治療策略。例如，截至2023年3月，美國臨床腫瘤學會 (ASCO) 旗下的線上資源網站 Cancer.Net 估計，2023年美國將新增約238,340例肺癌病例，較2022年的236,000例增加。肺癌發生率的上升是癌症診斷設備市場成長的主要驅動力。

癌症診斷市場的一個新興趨勢是使用基於人工智慧的系統進行癌症檢測。人工智慧在提高乳癌和肺癌相關診斷程序中影像檢測的準確性方面發揮關鍵作用。它的功能有助於在早期發現癌症，從而有助於提高檢測的準確性。在肺癌篩檢中，人工智慧的參與可以減少假陽性，最終提高癌症檢測的準確性。特別是，聖地牙哥海軍醫療中心和谷歌人工智慧研究院的研究人員開發了一種由人工智慧驅動的解決方案，用於自主評估淋巴結活體組織切片，將轉移性乳癌檢測的準確率顯著提高至99%。

癌症診斷設備市場的主要企業正專注於包括人工智慧 (AI) 在內的技術進步，以在行業中建立競爭優勢，例如 QAi Prostate，這是一款專門用於前列腺癌檢測的尖端癌症診斷工具。值得注意的是，2023 年 3 月，總部位於新加坡的 Qritive 公司推出了 QAi Prostate，該公司專門為病理學家提供人工智慧診斷解決方案。這款創新的人工智慧工具採用機器學習演算法，能夠準確地識別和分類前列腺組織樣本中的良性和惡性區域。它為病理學家提供了寶貴的資源，幫助他們準確檢測前列腺癌，同時區分所分析組織樣本中的良性和惡性區域。

癌症診斷市場受美國食品藥物管理局 (FDA) 監管，該機構對 MRI 和 NMR 等癌症診斷設備實施嚴格的監管。由於涉及中等風險，這些設備被歸類為 II 類。此分類規定了具體的監管義務，包括性能標準、上市前資料要求、上市後監督和標籤要求。特別是，設備標籤必須包含詳細資訊，例如禁忌症、副作用、注意事項、警告和使用說明。這些監管措施為癌症診斷設備製造商設定了查核點。

癌症診斷市場的主要企業包括雅培實驗室、碧迪公司、Hologic、通用電氣醫療有限公司、賽默飛世爾科技、西門子醫療有限公司、Accuray、醫科達公司、CR BardInc、Biogenex Laboratories、Eckert & Ziegler BEBIG、Veracyte、PathAI、Bio-Rad Laboratories、Bionox & Ziegler BEBIG、Veracyte、PathAI、Bio-Rad Sciences、禮來公司、Genomic Health、Affymetrix、安捷倫科技、Adaptive Biotechnologies、Biocartis、Biocept、Cancer Genetics Inc、Caris Lifesciences、Cepheid、 表觀基因 AG、Exact Sciences、Foundation Medicine、Genmark Diagnostics、GuardIBant、Hanonostics、Hanod . Technologies、Natera、NeoGenomics、Oncura Inc.、PerkinElmer、Personal Genome Diagnostics， Qiagen、Roche Diagnostics、TheraGenics Corporation 和 Varian Medical Systems, Inc.

2024年，癌症診斷市場最大的地區是北美。亞太地區是全球癌症診斷市場的第二大地區。癌症診斷市場報告涵蓋亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。

癌症診斷市場報告涵蓋澳大利亞、中國、印度、印度尼西亞、日本、韓國、孟加拉國、泰國、越南、馬來西亞、新加坡、菲律賓、香港、紐西蘭、美國、加拿大、墨西哥、巴西、智利、阿根廷、哥倫比亞、秘魯、法國、德國、英國、奧地利、比利時、丹麥、芬蘭、愛爾蘭、義大利、荷蘭、挪威、葡萄牙、西班牙、瑞典、瑞士、俄羅斯、捷克共和國、波蘭、羅馬尼亞、烏克蘭、沙烏地阿拉伯、以色列、伊朗、土耳其、阿拉伯聯合大公國、埃及、奈及利亞和南非等國家。

癌症診斷市場包括病理學設備（玻片染色系統、組織處理系統、細胞處理器、PCR設備、NGS設備和其他病理學設備）、影像設備（CT系統、超音波系統、MRI系統、乳房X光攝影系統和核子醫學攝影影像系統）以及切片檢查。該市場的價值是指出廠價，即商品製造商或生產商向其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接向最終客戶銷售的商品價值。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球癌症診斷：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球癌症診斷市場：成長率分析
  • 全球癌症診斷市場表現：規模與成長，2019-2024
  • 全球癌症診斷市場預測：規模與成長，2024-2029年，2034年
  • 全球癌症診斷：總目標市場（TAM）

第6章 市場細分

  • 全球癌症診斷市場（依產品、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 伴隨診斷
  • 分子診斷
  • 全球癌症診斷市場的應用、表現與預測，2019-2024 年、2024-2029 年、2034 年
  • 切片檢查
  • 內視鏡檢查
  • 腫瘤生物標記檢測
  • 影像學
  • 全球癌症診斷市場（按癌症類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
  • 子宮頸癌
  • 乳癌
  • 肝癌
  • 血癌
  • 腎癌
  • 大腸直腸癌
  • 胰臟癌
  • 卵巢癌
  • 黑色素瘤
  • 其他用途
  • 全球癌症診斷市場（按最終用戶、績效和預測），2019-2024 年、2024-2029 年、2034 年
  • 癌症研究所
  • 診斷實驗室
  • 醫院
  • 其他最終用戶
  • 全球癌症診斷市場：伴隨診斷細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 基於生物標記的伴隨診斷
  • 基於基因檢測的伴隨診斷
  • 基於免疫組織化學的伴隨診斷
  • 基於PCR的伴隨診斷
  • 其他伴隨診斷
  • 全球癌症診斷市場：依分子診斷細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 聚合酵素鏈鎖反應（PCR）診斷
  • 次世代定序（NGS）診斷
  • 原位雜合技術診斷
  • 基於微陣列的診斷
  • DNA或RNA萃取試劑套件
  • 其他分子診斷

第7章 區域和國家分析

  • 全球癌症診斷市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球癌症診斷市場：依國家、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 孟加拉市場

第16章 泰國市場

第17章 越南市場

第18章 馬來西亞市場

第19章：新加坡市場

第20章：菲律賓市場

第21章 香港市場

第22章：紐西蘭市場

第23章 西歐市場

第24章英國市場

第25章：德國市場

第26章：法國市場

第27章：義大利市場

第28章：西班牙市場

第29章：西班牙市場

第30章：奧地利市場

第31章：比利時市場

第32章：丹麥市場

第33章 芬蘭市場

第34章：愛爾蘭市場

第35章：荷蘭市場

第36章：挪威市場

第37章：葡萄牙市場

第38章：瑞典市場

第39章：瑞士市場

第40章 東歐市場

第41章俄羅斯市場

第42章 捷克共和國市場

第43章：波蘭市場

第44章：羅馬尼亞市場

第45章：烏克蘭市場

第46章 北美市場

第47章美國市場

第48章：加拿大市場

第50章：南美市場

第51章：巴西市場

第52章 智利市場

第53章：阿根廷市場

第54章：哥倫比亞市場

第55章秘魯市場

第56章 中東市場

第57章：沙烏地阿拉伯市場

第58章：以色列市場

第59章 伊朗市場

第60章 土耳其市場

第61章：阿拉伯聯合大公國市場

第62章 非洲市場

第63章埃及市場

第64章 奈及利亞市場

第65章南非市場

第66章：競爭格局與公司概況

  • 癌症診斷市場：競爭格局
  • 癌症診斷市場：公司簡介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
    • Hologic Overview, Products and Services, Strategy and Financial Analysis
    • GE Healthcare Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis

第 67 章：其他領先和創新企業

  • Siemens Healthcare GmbH
  • Accuray
  • Elekta AB
  • CR Bard Inc.
  • Biogenex Laboratories
  • Eckert & Ziegler BEBIG
  • Veracyte
  • PathAI
  • Bio-Rad Laboratories
  • Biochain
  • DiagnoCure
  • Illumina
  • Myriad Genetics
  • CompanionDx
  • Epic Sciences

第 68 章：全球市場競爭基準化分析與儀錶板

第69章：重大併購

第70章近期市場趨勢

第71章：高潛力市場國家、細分市場與策略

  • 2029年癌症診斷市場：提供新機會的國家
  • 2029年癌症診斷市場：細分領域帶來新機會
  • 2029年癌症診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第72章 附錄

簡介目錄
Product Code: r32435u

Cancer diagnostics involves the processes, tests, and technologies used to detect the presence of cancer in individuals. This area includes various methods aimed at identifying, staging, and characterizing cancer, enabling timely and effective treatment.

The primary offerings within the cancer diagnostics sector include companion diagnostics and molecular diagnostics. Molecular diagnostics involve laboratory procedures to detect particular proteins, genes, or molecules indicating the presence of cancer. Diagnostic methods in cancer assessments encompass biopsies, endoscopies, tumor biomarker tests, and imaging. These diagnostic tools cater to various applications, including cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others. They are utilized by diverse end-users like cancer research institutes, diagnostic laboratories, hospitals, and related entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer diagnostics market size has grown strongly in recent years. It will grow from $23.24 billion in 2024 to $25.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing cancer incidence, cancer screening programs, personalized medicine, public awareness.

The cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $40.07 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to emerging markets growth, regulatory support, artificial intelligence (ai) and machine learning, early detection and intervention. Major trends in the forecast period include liquid biopsies, multi-omics approaches, point-of-care testing, screening and early intervention campaigns.

The forecast of 12.0% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for fluorescence in situ hybridization (FISH) probes and digital pathology slide scanners, sourced from key regions such as Israel and the Netherlands, which could lead to reduced testing capacity and increased oncology care costs.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The significant driver behind the cancer diagnostics market is the high prevalence of various cancer types, compelling a larger number of individuals to seek diagnosis and treatment. These escalating cancer incidents have led to cancer becoming the second most common cause of death globally, as per the World Health Organization (WHO). Projections by the National Cancer Institute (NCI) estimate new annual cancer cases to increase to 23.6 million by the year 2030.

The growth of the cancer diagnostic device market is anticipated to be significantly propelled by the rising incidence of lung cancer. Lung cancer, characterized by the uncontrolled growth of abnormal cells in lung tissues, is a prevalent and deadly form of cancer. Cancer diagnostic devices play a crucial role in detecting, diagnosing, and monitoring lung cancer, aiding healthcare professionals in identifying its presence, determining its type and stage, and guiding treatment strategies. For example, as of March 2023, Cancer.Net, an online resource affiliated with the American Society of Clinical Oncology (ASCO), has estimated that the United States will witness around 238,340 new cases of lung cancer in 2023, an increase from the 236,000 cases diagnosed in 2022. This escalating incidence of lung cancer is a key driver for the growth of the cancer diagnostic device market.

The emerging trend within the cancer diagnostics market is the utilization of AI-based systems for cancer detection. AI plays a pivotal role in enhancing the precision of image detection in diagnostic procedures related to breast and lung cancer. Its capabilities aid in identifying cancers during their early stages, thereby contributing to improved detection accuracy. In lung cancer screening, AI's involvement results in a reduction in false-positive occurrences, ultimately enhancing accuracy in cancer detection. Notably, researchers at the Naval Medical Center San Diego and Google AI research division developed an AI-driven solution for autonomous evaluation of lymph node biopsies, significantly enhancing metastatic breast cancer detection accuracy to 99%.

Prominent companies within the cancer diagnostic device market are directing their efforts toward technological advancements involving artificial intelligence (AI), as seen with QAi Prostate, to establish a competitive advantage in the industry. QAi Prostate is a cutting-edge cancer diagnostic tool specifically designed for prostate cancer detection. Notably, in March 2023, Qritive, a Singapore-based enterprise specializing in AI-powered diagnostic solutions for pathologists, introduced QAi Prostate. This innovative AI-driven tool employs machine learning algorithms to precisely recognize and categorize malignant and benign regions within prostate tissue samples. It serves as a valuable resource for pathologists, aiding in the accurate detection of prostate cancer while distinguishing between malignant and benign areas in the analyzed tissue samples.

The cancer diagnostics market is overseen by the FDA, which applies stringent regulations to cancer diagnostic devices like MRI and NMR. These devices fall under the Class II category due to their moderate associated risk. This classification subjects them to specific regulatory mandates encompassing performance standards, premarket data requirements, post-market surveillance, and necessary labelling conditions. Notably, device labelling must include details like contraindications, adverse reactions, precautions, warnings, and usage instructions. Such regulatory measures serve as a checkpoint for manufacturers producing cancer diagnostic devices.

Major companies operating in the cancer diagnostics market include Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Elekta AB, C.R. BardInc., Biogenex Laboratories, Eckert & Ziegler BEBIG, Veracyte, PathAI, Bio-Rad Laboratories, Biochain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Eli Lilly and Co, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, IBA group, Invitae Corporation, Medtronic PLC, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics, Theragenics Corporation, Varian Medical SystemsInc.

North America was the largest region in the cancer diagnostics market in 2024. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cancer diagnostics market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Products: Companion Diagnostics; Molecular Diagnostics
  • 2) By Method: Biopsy; Endoscopy; Tumor Biomarker Tests; Imaging
  • 3) By Application: Cervical Cancer; Breast Cancer; Liver Cancer; Blood Cancer; Kidney Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Melanoma; Other Applications
  • 4) By End-User: Cancer Research Institutes; Diagnostic Laboratories; Hospitals; Other End Users
  • Subsegments:
  • 1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics; Genetic Testing-Based Companion Diagnostics; Immunohistochemistry-Based Companion Diagnostics; PCR-Based Companion Diagnostics; Other Companion Diagnostics;
  • 2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics; Next-Generation Sequencing (NGS) Diagnostics; In Situ Hybridization Diagnostics; Microarray-Based Diagnostics; DNA Or RNA Extraction Kits; Other Molecular Diagnostics
  • Companies Mentioned: Abbott Laboratories; Becton Dickinson and Company; Hologic; GE Healthcare Ltd.; Thermo Fisher Scientific; Siemens Healthcare GmbH; Accuray; Elekta AB; C.R. BardInc.; Biogenex Laboratories; Eckert & Ziegler BEBIG; Veracyte; PathAI; Bio-Rad Laboratories; Biochain; DiagnoCure; Illumina; Myriad Genetics; CompanionDx; Epic Sciences; Eli Lilly and Co; Genomic Health; Affymetrix; Agilent Technologies; Adaptive Biotechnologies; Biocartis; Biocept; Cancer Genetics Inc.; Caris Life Sciences; Cepheid; Epigenomics AG; Exact Sciences; Foundation Medicine; GenMark Diagnostics; Guardant Health; HalioDX; IBA group; Invitae Corporation; Medtronic plc; NanoString Technologies; Natera; NeoGenomics; Oncura Inc.; PerkinElmer; Personal Genome Diagnostics; Qiagen; Roche Diagnostics; Theragenics Corporation; Varian Medical SystemsInc.
  • Countries: Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Diagnostics Market Characteristics

3. Cancer Diagnostics Market Trends And Strategies

4. Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cancer Diagnostics Total Addressable Market (TAM)

6. Cancer Diagnostics Market Segmentation

  • 6.1. Global Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Companion Diagnostics
  • Molecular Diagnostics
  • 6.2. Global Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biopsy
  • Endoscopy
  • Tumor Biomarker Tests
  • Imaging
  • 6.3. Global Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cervical Cancer
  • Breast Cancer
  • Liver Cancer
  • Blood Cancer
  • Kidney Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Melanoma
  • Other Applications
  • 6.4. Global Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Hospitals
  • Other End Users
  • 6.5. Global Cancer Diagnostics Market, Sub-Segmentation Of Companion Diagnostics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biomarker-Based Companion Diagnostics
  • Genetic Testing-Based Companion Diagnostics
  • Immunohistochemistry-Based Companion Diagnostics
  • PCR-Based Companion Diagnostics
  • Other Companion Diagnostics
  • 6.6. Global Cancer Diagnostics Market, Sub-Segmentation Of Molecular Diagnostics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR) Diagnostics
  • Next-Generation Sequencing (NGS) Diagnostics
  • In Situ Hybridization Diagnostics
  • Microarray-Based Diagnostics
  • DNA Or RNA Extraction Kits
  • Other Molecular Diagnostics

7. Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Diagnostics Market

  • 8.1. Asia-Pacific Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Diagnostics Market

  • 9.1. China Cancer Diagnostics Market Overview
  • 9.2. China Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Diagnostics Market

  • 10.1. India Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Diagnostics Market

  • 11.1. Japan Cancer Diagnostics Market Overview
  • 11.2. Japan Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Diagnostics Market

  • 12.1. Australia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Diagnostics Market

  • 13.1. Indonesia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Diagnostics Market

  • 14.1. South Korea Cancer Diagnostics Market Overview
  • 14.2. South Korea Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Bangladesh Cancer Diagnostics Market

  • 15.1. Bangladesh Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.2. Bangladesh Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Bangladesh Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. Thailand Cancer Diagnostics Market

  • 16.1. Thailand Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. Thailand Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. Thailand Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Vietnam Cancer Diagnostics Market

  • 17.1. Vietnam Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Vietnam Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Vietnam Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. Malaysia Cancer Diagnostics Market

  • 18.1. Malaysia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. Malaysia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. Malaysia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Singapore Cancer Diagnostics Market

  • 19.1. Singapore Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Singapore Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Singapore Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Philippines Cancer Diagnostics Market

  • 20.1. Philippines Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Philippines Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Philippines Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Hong Kong Cancer Diagnostics Market

  • 21.1. Hong Kong Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.2. Hong Kong Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Hong Kong Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. New Zealand Cancer Diagnostics Market

  • 22.1. New Zealand Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. New Zealand Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. New Zealand Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. Western Europe Cancer Diagnostics Market

  • 23.1. Western Europe Cancer Diagnostics Market Overview
  • 23.2. Western Europe Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. Western Europe Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. Western Europe Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. UK Cancer Diagnostics Market

  • 24.1. UK Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.2. UK Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. UK Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Germany Cancer Diagnostics Market

  • 25.1. Germany Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.2. Germany Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Germany Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. France Cancer Diagnostics Market

  • 26.1. France Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.2. France Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. France Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Italy Cancer Diagnostics Market

  • 27.1. Italy Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Italy Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Italy Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Spain Cancer Diagnostics Market

  • 28.1. Spain Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.2. Spain Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Spain Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Spain Cancer Diagnostics Market

  • 29.1. Spain Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.2. Spain Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Spain Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Austria Cancer Diagnostics Market

  • 30.1. Austria Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 30.2. Austria Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 30.3. Austria Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

31. Belgium Cancer Diagnostics Market

  • 31.1. Belgium Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 31.2. Belgium Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 31.3. Belgium Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

32. Denmark Cancer Diagnostics Market

  • 32.1. Denmark Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 32.2. Denmark Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 32.3. Denmark Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

33. Finland Cancer Diagnostics Market

  • 33.1. Finland Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 33.2. Finland Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 33.3. Finland Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

34. Ireland Cancer Diagnostics Market

  • 34.1. Ireland Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 34.2. Ireland Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 34.3. Ireland Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

35. Netherlands Cancer Diagnostics Market

  • 35.1. Netherlands Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 35.2. Netherlands Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 35.3. Netherlands Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

36. Norway Cancer Diagnostics Market

  • 36.1. Norway Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 36.2. Norway Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 36.3. Norway Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

37. Portugal Cancer Diagnostics Market

  • 37.1. Portugal Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 37.2. Portugal Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 37.3. Portugal Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

38. Sweden Cancer Diagnostics Market

  • 38.1. Sweden Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 38.2. Sweden Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 38.3. Sweden Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

39. Switzerland Cancer Diagnostics Market

  • 39.1. Switzerland Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 39.2. Switzerland Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 39.3. Switzerland Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

40. Eastern Europe Cancer Diagnostics Market

  • 40.1. Eastern Europe Cancer Diagnostics Market Overview
  • 40.2. Eastern Europe Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 40.3. Eastern Europe Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 40.4. Eastern Europe Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

41. Russia Cancer Diagnostics Market

  • 41.1. Russia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 41.2. Russia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 41.3. Russia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

42. Czech Republic Cancer Diagnostics Market

  • 42.1. Czech Republic Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 42.2. Czech Republic Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 42.3. Czech Republic Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

43. Poland Cancer Diagnostics Market

  • 43.1. Poland Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 43.2. Poland Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 43.3. Poland Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

44. Romania Cancer Diagnostics Market

  • 44.1. Romania Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 44.2. Romania Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 44.3. Romania Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

45. Ukraine Cancer Diagnostics Market

  • 45.1. Ukraine Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 45.2. Ukraine Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 45.3. Ukraine Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

46. North America Cancer Diagnostics Market

  • 46.1. North America Cancer Diagnostics Market Overview
  • 46.2. North America Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 46.3. North America Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 46.4. North America Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

47. USA Cancer Diagnostics Market

  • 47.1. USA Cancer Diagnostics Market Overview
  • 47.2. USA Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 47.3. USA Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 47.4. USA Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

48. Canada Cancer Diagnostics Market

  • 48.1. Canada Cancer Diagnostics Market Overview
  • 48.2. Canada Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 48.3. Canada Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 48.4. Canada Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 49.1. Mexico Cancer Diagnostics Market Overview
  • 49.2. Mexico Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 49.3. Mexico Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 49.4. Mexico Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

50. South America Cancer Diagnostics Market

  • 50.1. South America Cancer Diagnostics Market Overview
  • 50.2. South America Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 50.3. South America Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 50.4. South America Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

51. Brazil Cancer Diagnostics Market

  • 51.1. Brazil Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 51.2. Brazil Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 51.3. Brazil Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

52. Chile Cancer Diagnostics Market

  • 52.1. Chile Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 52.2. Chile Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 52.3. Chile Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

53. Argentina Cancer Diagnostics Market

  • 53.1. Argentina Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 53.2. Argentina Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 53.3. Argentina Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

54. Colombia Cancer Diagnostics Market

  • 54.1. Colombia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 54.2. Colombia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 54.3. Colombia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

55. Peru Cancer Diagnostics Market

  • 55.1. Peru Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 55.2. Peru Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 55.3. Peru Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

56. Middle East Cancer Diagnostics Market

  • 56.1. Middle East Cancer Diagnostics Market Overview
  • 56.2. Middle East Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 56.3. Middle East Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 56.4. Middle East Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

57. Saudi Arabia Cancer Diagnostics Market

  • 57.1. Saudi Arabia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 57.2. Saudi Arabia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 57.3. Saudi Arabia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

58. Israel Cancer Diagnostics Market

  • 58.1. Israel Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 58.2. Israel Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 58.3. Israel Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

59. Iran Cancer Diagnostics Market

  • 59.1. Iran Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 59.2. Iran Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 59.3. Iran Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

60. Turkey Cancer Diagnostics Market

  • 60.1. Turkey Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 60.2. Turkey Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 60.3. Turkey Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

61. United Arab Emirates Cancer Diagnostics Market

  • 61.1. United Arab Emirates Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 61.2. United Arab Emirates Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 61.3. United Arab Emirates Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

62. Africa Cancer Diagnostics Market

  • 62.1. Africa Cancer Diagnostics Market Overview
  • 62.2. Africa Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 62.3. Africa Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 62.4. Africa Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

63. Egypt Cancer Diagnostics Market

  • 63.1. Egypt Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 63.2. Egypt Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 63.3. Egypt Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

64. Nigeria Cancer Diagnostics Market

  • 64.1. Nigeria Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 64.2. Nigeria Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 64.3. Nigeria Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

65. South Africa Cancer Diagnostics Market

  • 65.1. South Africa Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 65.2. South Africa Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 65.3. South Africa Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

66. Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 66.1. Cancer Diagnostics Market Competitive Landscape
  • 66.2. Cancer Diagnostics Market Company Profiles
    • 66.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.2. Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.3. Hologic Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.4. GE Healthcare Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.5. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis

67. Cancer Diagnostics Market Other Major And Innovative Companies

  • 67.1. Siemens Healthcare GmbH
  • 67.2. Accuray
  • 67.3. Elekta AB
  • 67.4. C.R. Bard Inc.
  • 67.5. Biogenex Laboratories
  • 67.6. Eckert & Ziegler BEBIG
  • 67.7. Veracyte
  • 67.8. PathAI
  • 67.9. Bio-Rad Laboratories
  • 67.10. Biochain
  • 67.11. DiagnoCure
  • 67.12. Illumina
  • 67.13. Myriad Genetics
  • 67.14. CompanionDx
  • 67.15. Epic Sciences

68. Global Cancer Diagnostics Market Competitive Benchmarking And Dashboard

69. Key Mergers And Acquisitions In The Cancer Diagnostics Market

70. Recent Developments In The Cancer Diagnostics Market

71. Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 71.1 Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 71.2 Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 71.3 Cancer Diagnostics Market In 2029 - Growth Strategies
    • 71.3.1 Market Trend Based Strategies
    • 71.3.2 Competitor Strategies

72. Appendix

  • 72.1. Abbreviations
  • 72.2. Currencies
  • 72.3. Historic And Forecast Inflation Rates
  • 72.4. Research Inquiries
  • 72.5. The Business Research Company
  • 72.6. Copyright And Disclaimer